Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer
Journal of Gastrointestinal Cancer · 2025
DOI: 10.1007/s12029-024-01120-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Gastrointestinal Cancer, 2025. Verfasst von Miaomiao Gou und 4 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BACKGROUND: The survival benefit from later-line treatment for patients with metastatic colorectal cancer (mCRC) remains disappointing. Here, in a real-world study, we were aimed to evaluate which choice will affect the survival of mCRC patients after standard treatment in Chinese patients. METHODS: A total of 129 patients with refractory mCRC were involved in the study. They received targeted monotherapy or combined with chemo-agents or PD-1 inhibitor before death. Overall survival (OS) and progression-free survival (PFS) were reviewed and evaluated from clinical features and treatment options. RESULTS: Among the 129 patients, the median age was 56 years (25-81). The mOS from third-line was 12.5 months. OS of patients who treated with chemo plus targeted therapy group in third-line was shown to be superior to pd-1 inhibitor in combination with antiangiogenic agents or antiangiogenic monotherapy group (15.6 m vs. 10.5 m vs. 8.4 m, p 0.05). The mPFS was 3.5 months in patients who had administered with antiangiogenic targeted agents plus anti-pd-1 and 4.7 months in chemo plus targeted therapy group and 2.2 months in the other group. In the triplet drugs group, preliminary results showed that ORR was 13.3% and DCR was 80%. The median PFS was 5.1 m, and the median OS was 10.6 m. CONCLUSIONS: Triplet drugs resulted in significantly longer overall survival, and immunotherapy may have limited benefit in MSS type CRC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China.
- The Eighth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China.
- Medical Oncology Department, The Second Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China.
- Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China. wangzkme@sohu.com.
- Medical Oncology Department, The Fifth Medical Center, Chinese People's Liberation Army General Hospital, Beijing, People's Republic of China. daigh60@sohu.com.
Zitieren
APA
Gou, M., Qian, N., Zhang, Y., Wang, Z., & Dai, G. (2025). Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer. https://doi.org/10.1007/s12029-024-01120-9
Vancouver
Gou M, Qian N, Zhang Y, Wang Z, Dai G. Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer. Journal of Gastrointestinal Cancer. 2025. doi:10.1007/s12029-024-01120-9
BibTeX
@article{Gou2025,
author = {Gou, Miaomiao and Qian, Niansong and Zhang, Yong and Wang, Zhikuan and Dai, Guanghai},
title = {Third- or Further-Line Treatment in Patients with MSS Type Metastatic Colorectal Cancer},
journal = {Journal of Gastrointestinal Cancer},
year = {2025},
doi = {10.1007/s12029-024-01120-9}
}
EUVIMED